Dr. Kiran Turaga on Regional Therapies in Melanoma

Video

In Partnership With:

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses regional therapies in melanoma.

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses regional therapies in melanoma.

The application of regional therapies for melanoma has been proven to be a very effective treatment for intransit melanoma, says Turaga.

Regional therapies for melanoma include isolated limb infusions and isolated limb perfusions. Isolated limb infusions are an attractive option because they are percutaneous, minimally invasive, and patients can go home quickly after treatment, says Turaga. The compete response rates ranges from 40 to 70%. A meta analysis looking at regional therapies for melanoma found that the overall survival in this population was about 41 months.

Questions remain regarding how to integrate immune modulating agents along with regional therapies for melanoma.

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh